Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy
Muscle & Nerve · 2025
DOI: 10.1002/mus.28321 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Sarah P Sherlock und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Muscle, Skeletal, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Pfizer.
Abstract (Originalsprache)
Introduction/Aims Improved methodologies to monitor the progression of Duchenne muscular dystrophy (DMD) are needed, especially in the context of clinical trials. We report changes in muscle magnetic resonance imaging (MRI) parameters in participants with DMD, including changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI) and their relationship to changes in functional parameters.
Methods
MRI data were obtained as part of a clinical study (NCT02310763) of domagrozumab, an antibody‐targeting myostatin that negatively regulates skeletal muscle mass. This post hoc analysis evaluated participants with Dixon MRI data and corresponding functional data at baseline and weeks 49 and 97. Images were analyzed to evaluate changes in adductors, hamstrings, and quadriceps.
Results
There was a positive correlation between increases in LMV and function. LMV changes in adductors ( R = 0.51) and quadriceps ( R = 0.54) showed a stronger correlation with function than LMV changes in hamstrings ( R = 0.30). There was a negative correlation between MFF and MFI, respectively, and function in adductors ( R = −0.57, R = −0.42), quadriceps ( R = −0.59, R = −0.50), and hamstrings ( R = −0.53, R = −048). Participants with preserved North Star Ambulatory Assessment scores had high total LMV (LMV tot ) and low total MFI (MFI tot ). Low ratios of LMV tot to MFI tot , or participants with small LMV tot and high MFI tot , appeared to have a rapid decline in function and loss of ambulation.
Discussion
These findings support the use of MRI biomarkers as potential surrogate endpoints in clinical trials of patients with DMD. Trial Registration: ClinicalTrials.gov identifiers: NCT02310763
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Inc, Cambridge, Massachusetts, USA.
- Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
- Department of Statistics, Quanticate Clinical Research Organization, Ontario, Canada.
- AMRA Medical AB, Linköping, Sweden.
ORCID-Profile: Sarah P Sherlock, Allison McCrady, Markus Karlsson
Förderung
- NIGMS NIH HHS
- Pfizer
Zitieren
APA
Sherlock, S. P., McCrady, A., Palmer, J., Aghamolaey, H., Ahlgren, A., Widholm, P., Dahlqvist Leinhard, O., & Karlsson, M. (2025). Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy. Muscle & Nerve. https://doi.org/10.1002/mus.28321
Vancouver
Sherlock SP, McCrady A, Palmer J, Aghamolaey H, Ahlgren A, Widholm P, et al. Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy. Muscle & Nerve. 2025. doi:10.1002/mus.28321
BibTeX
@article{Sherlock2025,
author = {Sherlock, Sarah P and McCrady, Allison and Palmer, Jeffrey and Aghamolaey, Haleh and Ahlgren, André and Widholm, Per and Dahlqvist Leinhard, Olof and Karlsson, Markus},
title = {Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28321}
}
EUVIMED